{"gene":"EGLN2","run_date":"2026-06-09T23:54:42","timeline":{"discoveries":[{"year":2002,"finding":"PHD1 (EGLN2) is an iron(II)- and 2-oxoglutarate-dependent oxygenase that hydroxylates proline residues in HIF-1α; mutation of the arginine proposed to bind 2-oxoglutarate and of the 2His-1-carboxylate iron(II) binding motif dramatically reduces activity; the oxygen of the product alcohol derives >95% from dioxygen.","method":"In vitro enzymatic assay with active-site mutagenesis; isotope labeling to trace oxygen source","journal":"Bioorganic & medicinal chemistry letters","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct in vitro enzymatic assay with mutagenesis of active-site residues and isotope-tracing; single paper but multiple orthogonal methods","pmids":["12039559"],"is_preprint":false},{"year":2002,"finding":"PHD1, PHD2, and PHD3 hydroxylate specific prolines in HIF-1α within the LXXLAP motif; PHD2 has the highest specific activity toward the primary hydroxylation site; the hydroxylacceptor proline itself is the only obligatory residue in the motif, with mutations tolerated at the -5, -2, and -1 positions.","method":"In vitro prolyl hydroxylation assay with systematic LXXLAP motif mutants; specific activity comparisons across PHD isoforms","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstituted in vitro enzymatic assay with systematic mutagenesis; single lab but multiple mutants tested with quantitative comparisons","pmids":["12181324"],"is_preprint":false},{"year":2004,"finding":"PHD1, PHD2, and PHD3 each contribute in a non-redundant manner to the regulation of both HIF-1α and HIF-2α; the relative contribution of each PHD isoform depends on its cellular abundance; isoforms show specificity for different prolyl hydroxylation sites within HIF-α subunits and a degree of selectivity between HIF-1α and HIF-2α.","method":"siRNA knockdown of each PHD isoform individually in multiple cell types; measurement of HIF-α levels and site-specific hydroxylation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — siRNA loss-of-function in multiple cell types with quantitative readouts; replicated across isoforms and cell lines in single study","pmids":["15247232"],"is_preprint":false},{"year":2003,"finding":"Ectopic expression of PHD1 (EGLN2) suppresses HIF-1α accumulation and VEGF secretion under hypoxia-mimetic conditions and inhibits tumor growth in vivo, associated with increased necrosis and decreased microvessel density.","method":"Overexpression of mPHD1 in colon carcinoma cells; xenograft tumor model in nude mice; immunostaining for HIF-1α and microvessel density","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain-of-function with defined cellular and in vivo phenotypic readouts; single lab, two orthogonal readouts (HIF suppression + tumor growth)","pmids":["14695194"],"is_preprint":false},{"year":2006,"finding":"PHD1 exists as two isoforms generated by alternative translational initiation; both isoforms are biologically active with similar HIF prolyl hydroxylase activity but differ in their responses to estrogen, cell confluence, and proteasomal inhibition, and differ markedly in protein stability. Both isoforms have the potential to interact with Siah ubiquitin ligase family members, though genetic studies indicated other proteolytic mechanisms control their stability under examined conditions.","method":"Characterization of isoforms by mutagenesis of start codons; HIF prolyl hydroxylase activity assays; protein stability assays; co-immunoprecipitation with Siah proteins","journal":"The Biochemical journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple assays (activity, stability, interaction) in single lab; direct demonstration of alternative initiation and functional equivalence","pmids":["16509823"],"is_preprint":false},{"year":2008,"finding":"Loss of Phd1 lowers oxygen consumption in skeletal muscle by reprogramming glucose metabolism from oxidative to anaerobic ATP production through activation of a PPARα pathway; this metabolic adaptation provides acute protection of myofibers against lethal ischemia; hypoxia tolerance relies primarily on Hif-2α and is not due to HIF-dependent angiogenesis, erythropoiesis, or vasodilation, but to reduced oxidative stress preserving mitochondrial respiration.","method":"Phd1 knockout mice; metabolic profiling; genetic epistasis with Hif-2α; histology of ischemic muscle; measurement of oxidative stress","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout with comprehensive metabolic profiling, epistasis analysis, and multiple orthogonal phenotypic readouts; replicated across conditions","pmids":["18176562"],"is_preprint":false},{"year":2008,"finding":"Human PHD1 purified from E. coli is an Fe2+- and 2-oxoglutarate-dependent enzyme with EC50 for Fe2+ of 0.64 μM; it is phosphorylated in vitro by protein kinase Cα at Ser-132, Ser-226, and Ser-234; mutation of Ser-132 or Ser-234 to Asp/Glu diminishes enzymatic activity to 25–60%, whereas mutation of Ser-226 has little effect.","method":"Recombinant protein purification; in vitro kinase assay with PKCα, PKA, CKI/II, Erk2; site-directed mutagenesis; prolyl hydroxylase activity assay","journal":"Journal of biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstituted in vitro enzymatic system with mutagenesis of phosphorylation sites; multiple kinases tested; activity consequences directly measured","pmids":["18710826"],"is_preprint":false},{"year":2008,"finding":"EGLN2 overexpression in renal oncocytoma increases ubiquitin-mediated destruction of HIF and concomitantly suppresses the expression of HIF-target genes including the pro-death BNIP3L gene.","method":"Gene expression profiling; functional overexpression studies in renal oncocytoma cells; ubiquitination assays for HIF","journal":"PLoS genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — functional overexpression with HIF ubiquitination readout; single study, limited mechanistic depth in abstract","pmids":["18773095"],"is_preprint":false},{"year":2009,"finding":"Nuclear import of PHD1 occurs in an importin α/β-dependent manner and relies on a nuclear localization signal (NLS); PHD1 is located exclusively in the nucleus, in contrast to PHD2 which cycles between nucleus and cytoplasm.","method":"Subcellular fractionation; importin α/β inhibition; fluorescence microscopy; NLS mutagenesis","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization experiments with mechanistic follow-up (NLS identification, importin dependence); single lab","pmids":["19631610"],"is_preprint":false},{"year":2009,"finding":"EglN2 (PHD1) is estrogen-inducible in breast carcinoma cells; EglN2 inactivation decreases Cyclin D1 levels and suppresses mammary gland proliferation in vivo in a HIF-independent manner; loss of EglN2 catalytic activity inhibits estrogen-dependent breast cancer tumorigenesis, rescued by exogenous Cyclin D1.","method":"EglN2 knockout mice; siRNA knockdown in breast cancer cells; mammary gland histology; Cyclin D1 rescue experiment; catalytic mutant studies","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo knockout phenotype, genetic rescue with Cyclin D1, catalytic activity requirement established; multiple orthogonal approaches in single study","pmids":["19878873"],"is_preprint":false},{"year":2011,"finding":"PHD1 interacts with ATF4 (but not PHD2) through the central region of ATF4; co-expression of PHD1 stabilizes ATF4 (opposite to PHD3 which destabilizes it); PHD1 represses the transcriptional activity of ATF4; ATF4 does not serve as a prolyl hydroxylation substrate of PHD1 (negative finding for hydroxylation); the interaction and transcriptional repression occur without prolyl hydroxylation of ATF4.","method":"Co-immunoprecipitation; in vitro prolyl hydroxylation assay; reporter assay for ATF4 transcriptional activity; protein stability assays; proline-to-alanine mutagenesis of ATF4","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP, in vitro hydroxylation assay confirming negative result, reporter assay; single lab, multiple orthogonal methods","pmids":["21951999"],"is_preprint":false},{"year":2013,"finding":"PHD1 is required for centrosome duplication and maturation through hydroxylation of the centrosomal protein Cep192 on proline 1717; this hydroxylation promotes binding of the E3 ubiquitin ligase SCF(Skp2), which ubiquitinates Cep192 and targets it for proteasomal degradation; PHD1 is also required for primary cilia formation.","method":"PHD1 loss-of-function; mass spectrometry identification of Cep192 as substrate; site-directed mutagenesis of Cep192 P1717; co-immunoprecipitation with SCF(Skp2); ubiquitination assay; centrosome/cilia imaging","journal":"Developmental cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct identification of hydroxylation site by MS, mutagenesis confirming functional requirement, biochemical reconstitution of SCF(Skp2) binding, multiple cellular readouts","pmids":["23932902"],"is_preprint":false},{"year":2014,"finding":"EglN2 hydroxylates FOXO3a on two specific prolyl residues in vitro and in vivo; hydroxylation of these sites prevents binding of the USP9x deubiquitinase, thereby promoting proteasomal degradation of FOXO3a; failure to hydroxylate FOXO3a promotes its accumulation, which suppresses Cyclin D1 transcription (because FOXO transcription factors can repress Cyclin D1).","method":"In vitro prolyl hydroxylation assay; mass spectrometry identification of hydroxylation sites; co-immunoprecipitation of FOXO3a with USP9x; protein stability assays; Cyclin D1 reporter/expression analysis","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro hydroxylation assay with site identification, mechanistic link to USP9x binding, downstream Cyclin D1 regulation; multiple orthogonal methods in single study","pmids":["24990963"],"is_preprint":false},{"year":2014,"finding":"A germline loss-of-function mutation in PHD1 causes reduced protein stability and compromised catalytic activity, associated with pheochromocytoma/paraganglioma and polycythemia, with inappropriate hypersensitivity of erythroid progenitors to EPO.","method":"Sequencing of patient samples; protein stability assays; in vitro catalytic activity measurement; erythroid progenitor EPO sensitivity assay","journal":"Journal of molecular medicine (Berlin, Germany)","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — catalytic activity and stability directly measured in patient mutant; single study with limited mechanistic follow-up","pmids":["25263965"],"is_preprint":false},{"year":2015,"finding":"PHD1 activity reinforces p53 binding to p38α kinase in a hydroxylation-dependent manner; following p53-p38α interaction and chemotherapeutic damage, p53 is phosphorylated at serine 15 and activated; active p53 interacts with the DNA helicase XPB to allow nucleotide excision repair; PHD1 knockdown (but not PHD2 or PHD3) prevents p53 activation upon chemotherapy in CRC cells.","method":"siRNA knockdown of PHD isoforms; co-immunoprecipitation of p53 with p38α; phospho-specific western blotting (p53 S15); interaction assay with XPB; mouse xenograft with 5-FU treatment","journal":"EMBO molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP, phospho-western, isoform-specific knockdown with clear phenotype; single lab, multiple methods","pmids":["26290450"],"is_preprint":false},{"year":2015,"finding":"PHD1 is phosphorylated by CDK2, CDK4, and CDK6 at serine 130; this phosphorylation fluctuates with the cell cycle and can be induced by oncogenic activation; S130 phosphorylation does not alter PHD1's intrinsic enzymatic activity but decreases its interaction with HIF1α (reducing PHD1 activity toward HIF1α) while increasing PHD1's activity toward Cep192.","method":"In vitro kinase assays with CDK2/4/6; phospho-specific antibody to pS130; cell cycle synchronization; co-immunoprecipitation of PHD1 with HIF1α; substrate activity assays toward HIF1α and Cep192","journal":"Journal of cell science","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay, mutagenesis, co-IP, and substrate activity assays; single lab but multiple orthogonal methods establishing mechanism","pmids":["26644182"],"is_preprint":false},{"year":2015,"finding":"EglN2 associates with the NRF1-PGC1α complex on chromatin under hypoxic conditions and promotes transcription of ferredoxin reductase (FDXR); EglN2 depletion decreases mitochondrial respiration and mitochondrial DNA content in breast cancer cells in a HIF1/2α-independent manner.","method":"Co-immunoprecipitation of EglN2 with NRF1 and PGC1α; chromatin immunoprecipitation (ChIP); gene expression profiling; mitochondrial respiration measurements; mtDNA quantification; siRNA knockdown","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, ChIP, functional metabolic readouts; multiple orthogonal methods in single study establishing EglN2 as transcriptional co-activator","pmids":["26492917"],"is_preprint":false},{"year":2016,"finding":"PHD1 deficiency in neurons reprograms glucose metabolism by enhancing flux through the oxidative pentose phosphate pathway (away from glycolysis), increasing redox buffering capacity to scavenge oxygen radicals; this provides neuroprotection against ischemia independently of collateral vessel network changes.","method":"PHD1 knockout mice; permanent brain ischemia model; metabolic flux analysis; ROS measurements; intracerebroventricular antisense oligonucleotide injection","journal":"Cell metabolism","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout with metabolic flux analysis and therapeutic antisense validation; multiple readouts and in vivo rescue","pmids":["26774962"],"is_preprint":false},{"year":2016,"finding":"Docetaxel activates PHD1 under hypoxic conditions through JNK2 signaling; activated PHD1 promotes polyubiquitination and proteasomal degradation of HIF-1α; pharmacological inhibition or siRNA knockdown of PHD1 prevents docetaxel-induced HIF-1α degradation and cancer cell death under hypoxia.","method":"JNK2 siRNA knockdown; PHD1 siRNA knockdown; pharmacological PHD1 inhibition; HIF-1α polyubiquitination assay; luciferase reporter for HIF-1 transcriptional activity; xenograft model","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA knockdown of JNK2 and PHD1 with mechanistic linkage, ubiquitination assay; single lab, multiple methods","pmids":["27263528"],"is_preprint":false},{"year":2017,"finding":"The E3 ubiquitin ligase SPOP (Cullin 3-based complex) recognizes and ubiquitinates EglN2, targeting it for proteasomal degradation; androgen receptor (AR) transcriptionally upregulates EglN2; SPOP loss-of-function mutations or AR amplification (common in prostate cancer) accumulate EglN2 protein.","method":"Co-immunoprecipitation of SPOP and EglN2; ubiquitination assay; SPOP loss-of-function mutants; AR ChIP/transcription assays; in vivo tumor models","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP, ubiquitination assay, SPOP mutant analysis; single lab, multiple methods establishing SPOP as EglN2 E3 ligase","pmids":["28089830"],"is_preprint":false},{"year":2017,"finding":"EglN2 acts as an FBW7 ubiquitin ligase substrate contributing to breast tumorigenesis; FBW7 overexpression leads to EglN2 downregulation in a GSK3β-dependent manner; depletion of FBW7 leads to EglN2 upregulation.","method":"FBW7 overexpression and knockdown; GSK3β inhibition; protein stability assays; co-immunoprecipitation; C3Tag transgenic mouse model","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP, genetic manipulation of FBW7/GSK3β, protein stability assays; single lab; GSK3β dependence confirmed","pmids":["28036276"],"is_preprint":false},{"year":2020,"finding":"PHD1 interacts with leucyl tRNA synthetase (LRS) and stabilizes it in a hydroxylation-independent manner; this interaction is promoted during oxygen and amino acid depletion and protects LRS from degradation; PHD1 knockout mice show impaired mTORC1 activation in response to leucine (but not growth factors or eccentric contractions), reduced muscle mass, and decreased LRS protein content.","method":"Co-immunoprecipitation of PHD1 with LRS; PHD1 catalytic mutant (hydroxylation-dead); PHD1KO mice; mTORC1 activity assays; leucine stimulation experiments; LRS activity measurements in human muscle biopsies","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal co-IP, catalytic mutant establishing hydroxylation independence, genetic knockout with specific mTORC1 readout, human validation; multiple orthogonal methods","pmids":["31924757"],"is_preprint":false},{"year":2021,"finding":"EGLN2 is a substrate of the E3 ubiquitin ligase MDM2, which interacts with the N-terminal of EGLN2 and mediates its K48-linked poly-ubiquitination, thereby facilitating proteasomal degradation of EGLN2.","method":"Co-immunoprecipitation of EGLN2 with MDM2; ubiquitination assay (K48 linkage); protein stability assays; domain mapping (N-terminal EGLN2)","journal":"Journal of cellular and molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP, K48-specific ubiquitination assay, domain mapping; single lab, multiple methods","pmids":["34687132"],"is_preprint":false},{"year":2024,"finding":"PHD1 hydroxylates Beclin1 on proline 54; VHL directly binds Beclin1 after PHD1-mediated hydroxylation; this binding inhibits the association of Beclin1-VPS34 complexes with ATG14L, thereby inhibiting autophagy initiation in response to nutrient deficiency; expression of non-hydroxylatable Beclin1 P54A abrogates VHL-mediated autophagy inhibition.","method":"In vitro hydroxylation assay; co-immunoprecipitation of VHL with Beclin1; P54A mutagenesis of Beclin1; Beclin1-VPS34-ATG14L complex assays; autophagy flux measurements; xenograft tumor models","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct in vitro hydroxylation, mutagenesis (P54A), reconstitution of VHL-Beclin1 interaction, multiple orthogonal methods including in vivo models","pmids":["38360997"],"is_preprint":false},{"year":2024,"finding":"Loss of EGLN2 in ALS models protects motor neurons and induces an astrocyte-specific downregulation of interferon-stimulated genes mediated via the STING protein; genetic deletion of EGLN2 restores this interferon response in patient iPSC-derived astrocytes.","method":"Egln2 genetic knockout; antisense oligonucleotide knockdown; zebrafish and mouse ALS models; single-nucleus RNA sequencing; iPSC-derived astrocyte experiments; STING pathway analysis","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic loss-of-function in multiple in vivo models with snRNA-seq pathway analysis; STING link established; single lab","pmids":["39255062"],"is_preprint":false},{"year":2025,"finding":"PHD1 hydroxylates RepoMan (CDCA2) on proline 604; siRNA depletion of PHD1 (but not PHD2) increases H3T3 phosphorylation in prometaphase-arrested cells; the non-hydroxylatable RepoMan P604A mutant reduces interaction of RepoMan with PP2A-B56γ, delays completion of mitosis, causes defects in chromosome alignment and segregation, and increases cell death.","method":"Mass spectrometry identification of P604 hydroxylation; siRNA depletion of PHD1/PHD2; RepoMan P604A mutagenesis; co-immunoprecipitation of RepoMan with PP2A-B56γ; H3T3 phosphorylation immunostaining; live-cell imaging of mitosis","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — MS identification of hydroxylation site, mutagenesis, co-IP, functional mitotic assays; preprint with multiple orthogonal methods but not yet peer-reviewed","pmids":["bio_10.1101_2025.05.06.652400"],"is_preprint":true},{"year":2017,"finding":"PHD1 inhibitors were identified with a novel monodentate binding mode; X-ray crystallography showed the triazolo N1 atom coordinates in a monodentate interaction with the active site Fe2+ ion, while the benzonitrile group accepts a hydrogen bond from Asn315.","method":"X-ray crystallography of PHD1-inhibitor complex; structure-activity relationship analysis","journal":"Journal of medicinal chemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — crystal structure with functional binding mode identified; single study, primarily pharmacological focus","pmids":["28594552"],"is_preprint":false},{"year":2023,"finding":"Elevation of intracellular alpha-ketoglutarate inhibits RANKL-induced osteoclastogenesis by suppressing NF-κB signaling in a PHD1 (EGLN2)-dependent manner; blockade of PHD1 expression (but not PHD2 or PHD3) reverses this suppression of RANKL-activated NF-κB signaling and antagonizes the inhibitory effects on osteoclastogenesis.","method":"PHD1/PHD2/PHD3 siRNA knockdown; NF-κB reporter assay; RANKL-induced osteoclast differentiation assay; DMOG (PHD competitive inhibitor) treatment","journal":"Nutrients","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — isoform-specific siRNA with NF-κB reporter and differentiation assays; single lab, multiple methods","pmids":["36771407"],"is_preprint":false},{"year":2025,"finding":"PHD1 (all three PHD isoforms) interacts with IKKα/β; overexpression of PHD1 and PHD2 (but PHD3 to a lesser extent) markedly reduces IKKα/β protein levels in a manner requiring PHD1/PHD2 active sites; PHD1 overexpression decreases mRNA levels of IL-1β, a downstream NF-κB target; FIH-1 does not interact with IKKα/β (negative finding).","method":"Co-immunoprecipitation of PHDs with IKKα/β; active-site mutants of PHD1/2/3; IL-1β mRNA measurement; IKKα/β protein level assays after PHD overexpression","journal":"The Journal of toxicological sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP with active-site mutants establishing catalytic dependence; single lab, multiple isoforms compared","pmids":["40024754"],"is_preprint":false}],"current_model":"EGLN2/PHD1 is a nuclear, iron(II)- and 2-oxoglutarate-dependent prolyl hydroxylase that regulates the stability of HIF-α subunits by hydroxylating specific proline residues, targeting them for VHL-mediated ubiquitination and proteasomal degradation; beyond HIF, it directly hydroxylates additional substrates including FOXO3a (blocking USP9x binding and promoting FOXO3a degradation, thereby relieving Cyclin D1 repression), Cep192 (promoting SCF(Skp2)-mediated ubiquitination to regulate centrosome duplication and cell-cycle progression), Beclin1 (enabling VHL binding to suppress autophagy), and RepoMan/CDCA2 (regulating PP2A-B56γ interaction and mitotic progression); in a hydroxylation-independent manner, PHD1 stabilizes leucyl tRNA synthetase to sustain mTORC1 responses to leucine, and associates with the NRF1-PGC1α complex to promote mitochondrial gene transcription; PHD1 substrate selectivity and activity are regulated by CDK2/4/6-mediated phosphorylation at S130, while PHD1 protein abundance is controlled by SPOP and FBW7 E3 ubiquitin ligases and by MDM2-mediated K48-linked ubiquitination."},"narrative":{"mechanistic_narrative":"EGLN2/PHD1 is a nuclear iron(II)- and 2-oxoglutarate-dependent prolyl hydroxylase that initiates regulated proteolysis of its substrates and broadly couples oxygen/metabolic status to cell-cycle, metabolic, and stress-response programs [PMID:12039559, PMID:12181324]. Its founding activity is hydroxylation of conserved prolines in HIF-1α/HIF-2α within the LXXLAP motif, marking HIF-α for ubiquitin-mediated degradation; PHD1 contributes non-redundantly with PHD2/PHD3, and its catalytic core depends on the 2His-1-carboxylate iron motif and the 2-oxoglutarate-binding arginine [PMID:12039559, PMID:12181324, PMID:15247232, PMID:14695194]. Beyond HIF, PHD1 hydroxylates a defined set of substrates to control proteostasis and complex assembly: it hydroxylates FOXO3a to block USP9x-mediated deubiquitination and drive FOXO3a degradation, relieving repression of Cyclin D1 in estrogen-dependent breast cancer in a HIF-independent, catalysis-dependent manner [PMID:19878873, PMID:24990963]; it hydroxylates Cep192 at Pro1717 to recruit SCF(Skp2) for centrosome-duplication control [PMID:23932902]; it hydroxylates Beclin1 at Pro54 to enable VHL binding and suppress autophagy initiation [PMID:38360997]; and it hydroxylates RepoMan/CDCA2 at Pro604 to regulate PP2A-B56γ interaction and mitotic progression [PMID:bio_10.1101_2025.05.06.652400]. PHD1 also acts through hydroxylation-independent routes—stabilizing leucyl tRNA synthetase to sustain leucine-driven mTORC1 signaling and muscle mass [PMID:31924757], and associating with the NRF1-PGC1α complex on chromatin to promote mitochondrial gene transcription and respiration [PMID:26492917]. Substrate selectivity is gated by CDK2/4/6 phosphorylation at Ser130, which lowers activity toward HIF1α while raising activity toward Cep192 [PMID:26644182], and PHD1 abundance is controlled by the E3 ligases SPOP, FBW7, and MDM2 [PMID:28089830, PMID:28036276, PMID:34687132]. Physiologically, Phd1 loss reprograms glucose metabolism toward anaerobic/pentose-phosphate flux to protect muscle and neurons against ischemia [PMID:18176562, PMID:26774962], and a germline loss-of-function mutation in PHD1 is associated with pheochromocytoma/paraganglioma and polycythemia [PMID:25263965].","teleology":[{"year":2002,"claim":"Established that EGLN2/PHD1 is an enzyme rather than a passive HIF binder, defining the catalytic chemistry that links oxygen availability to HIF-α fate.","evidence":"In vitro enzymatic assays with active-site mutagenesis and oxygen isotope tracing; reconstituted LXXLAP-motif mutagenesis across PHD isoforms","pmids":["12039559","12181324"],"confidence":"High","gaps":["Did not resolve PHD1-specific substrate preference beyond HIF","Cellular contribution relative to other isoforms untested in this work"]},{"year":2004,"claim":"Showed that PHD isoforms act non-redundantly with abundance-dependent and site-specific contributions, framing PHD1 as one functionally distinct arm of HIF regulation.","evidence":"Individual siRNA knockdown of each PHD across multiple cell types with site-specific hydroxylation readouts","pmids":["15247232"],"confidence":"High","gaps":["Did not define non-HIF substrates","Mechanism of isoform site selectivity unresolved"]},{"year":2003,"claim":"Demonstrated that PHD1 gain-of-function suppresses HIF/VEGF output and tumor growth, establishing a tumor-relevant consequence of HIF hydroxylation.","evidence":"PHD1 overexpression in colon carcinoma cells with xenograft tumor model and microvessel/HIF immunostaining","pmids":["14695194"],"confidence":"Medium","gaps":["Gain-of-function only","Endogenous PHD1 contribution not isolated"]},{"year":2006,"claim":"Revealed that PHD1 is produced as two alternatively initiated isoforms differing in stability and regulation, indicating layered control of PHD1 protein levels.","evidence":"Start-codon mutagenesis, activity/stability assays, and Co-IP with Siah ligases","pmids":["16509823"],"confidence":"Medium","gaps":["Dominant degradation pathway under physiological conditions unresolved","Functional distinction between isoforms in vivo untested"]},{"year":2008,"claim":"Identified PHD1 as a metabolic regulator in vivo, showing that Phd1 loss reprograms muscle glucose metabolism to confer ischemia tolerance largely independent of HIF-driven angiogenesis.","evidence":"Phd1 knockout mice with metabolic profiling, Hif-2α epistasis, and ischemic muscle histology","pmids":["18176562"],"confidence":"High","gaps":["Direct PPARα-pathway substrate of PHD1 not defined","Tissue-specificity of the metabolic switch unresolved"]},{"year":2008,"claim":"Provided the first phospho-regulatory layer on PHD1, showing PKCα phosphorylation sites tune catalytic activity.","evidence":"Recombinant PHD1 with in vitro kinase assays, site-directed mutagenesis, and activity measurements","pmids":["18710826"],"confidence":"High","gaps":["In vivo relevance of these sites not established","Did not link phosphorylation to substrate selectivity"]},{"year":2009,"claim":"Defined PHD1 as an exclusively nuclear hydroxylase imported via importin α/β, distinguishing its compartment from cytoplasm-cycling PHD2 and rationalizing nuclear substrate access.","evidence":"Subcellular fractionation, importin inhibition, NLS mutagenesis, and microscopy","pmids":["19631610"],"confidence":"Medium","gaps":["Whether localization is regulated by signaling untested","Link to specific nuclear substrates not made here"]},{"year":2009,"claim":"Uncovered a HIF-independent oncogenic function: PHD1 catalytic activity sustains Cyclin D1 and estrogen-dependent breast tumorigenesis.","evidence":"EglN2 knockout mice, breast cancer siRNA, catalytic-mutant studies, and Cyclin D1 rescue","pmids":["19878873"],"confidence":"High","gaps":["Direct hydroxylation substrate linking PHD1 to Cyclin D1 not yet identified in this work"]},{"year":2011,"claim":"Showed PHD1 can act as a non-catalytic protein partner, stabilizing and repressing ATF4 without hydroxylating it, broadening PHD1 function beyond proline hydroxylation.","evidence":"Reciprocal Co-IP, negative in vitro hydroxylation assay, and ATF4 reporter/stability assays","pmids":["21951999"],"confidence":"Medium","gaps":["Structural basis of PHD1-ATF4 binding unknown","Physiological context of ATF4 repression untested"]},{"year":2013,"claim":"Identified Cep192 as a direct hydroxylation substrate coupling PHD1 to centrosome duplication and ciliogenesis via SCF(Skp2)-mediated degradation.","evidence":"Loss-of-function, MS site identification, P1717 mutagenesis, SCF(Skp2) Co-IP, and centrosome/cilia imaging","pmids":["23932902"],"confidence":"High","gaps":["Oxygen-dependence of Cep192 hydroxylation in vivo not defined","Crosstalk with cell-cycle phosphorylation not yet linked"]},{"year":2014,"claim":"Connected PHD1 catalysis to its Cyclin D1 phenotype by showing FOXO3a hydroxylation blocks USP9x binding and drives FOXO3a degradation, relieving Cyclin D1 repression.","evidence":"In vitro hydroxylation with MS site mapping, FOXO3a-USP9x Co-IP, stability assays, and Cyclin D1 readouts","pmids":["24990963"],"confidence":"High","gaps":["Quantitative contribution of FOXO3a vs other substrates to Cyclin D1 unresolved"]},{"year":2015,"claim":"Identified CDK2/4/6 phosphorylation at Ser130 as a substrate-switch that biases PHD1 away from HIF1α toward Cep192, integrating PHD1 into cell-cycle control.","evidence":"In vitro CDK kinase assays, phospho-S130 antibody, cell-cycle synchronization, Co-IP, and substrate activity assays","pmids":["26644182"],"confidence":"High","gaps":["Whether S130 also reroutes activity to FOXO3a/Beclin1/RepoMan untested","Relation to PKCα sites unclear"]},{"year":2015,"claim":"Defined a hydroxylation-independent transcriptional co-activator role, with EglN2 joining the NRF1-PGC1α complex on chromatin to drive mitochondrial gene expression and respiration.","evidence":"Reciprocal Co-IP, ChIP, expression profiling, respiration and mtDNA measurements with siRNA","pmids":["26492917"],"confidence":"High","gaps":["Whether chromatin association requires catalytic residues untested","Direct DNA/chromatin contacts undefined"]},{"year":2015,"claim":"Linked PHD1 to genotoxic stress response, showing it reinforces p53-p38α interaction and p53 activation enabling nucleotide excision repair after chemotherapy.","evidence":"Isoform-specific siRNA, p53-p38α Co-IP, phospho-p53 S15 westerns, XPB interaction, and 5-FU xenograft","pmids":["26290450"],"confidence":"Medium","gaps":["Whether PHD1 hydroxylates a component of this complex unknown","Mechanism of p53-p38α reinforcement undefined"]},{"year":2014,"claim":"Provided human disease genetics linking a germline PHD1 loss-of-function mutation to pheochromocytoma/paraganglioma and polycythemia through reduced stability/activity.","evidence":"Patient sequencing, stability and catalytic activity assays, and erythroid progenitor EPO-sensitivity assay","pmids":["25263965"],"confidence":"Medium","gaps":["Single-variant evidence with limited mechanistic follow-up","Causal substrate driving the tumor/polycythemia phenotype unspecified"]},{"year":2016,"claim":"Extended the neuroprotective metabolic role, showing PHD1 deficiency boosts pentose-phosphate flux and redox buffering to protect neurons from ischemia.","evidence":"PHD1 knockout mice, brain ischemia model, metabolic flux and ROS analysis, and antisense oligonucleotide rescue","pmids":["26774962"],"confidence":"High","gaps":["Direct molecular target controlling the metabolic shift not defined","Cell-type contribution within brain unresolved"]},{"year":2016,"claim":"Showed PHD1 activity can be drug-induced to degrade HIF-1α, linking docetaxel/JNK2 signaling to PHD1-driven HIF turnover and cancer cell death under hypoxia.","evidence":"JNK2 and PHD1 siRNA, pharmacological inhibition, HIF-1α ubiquitination/reporter assays, and xenograft","pmids":["27263528"],"confidence":"Medium","gaps":["Mechanism by which JNK2 activates PHD1 undefined","Whether activation involves a known phospho-site untested"]},{"year":2017,"claim":"Identified SPOP and androgen-receptor signaling as a degradation/transcription axis controlling EglN2 abundance in prostate cancer.","evidence":"SPOP-EglN2 Co-IP, ubiquitination assays, SPOP mutants, AR transcription assays, and tumor models","pmids":["28089830"],"confidence":"Medium","gaps":["Degron in EglN2 recognized by SPOP not mapped","Downstream substrate consequences of EglN2 accumulation untested"]},{"year":2017,"claim":"Added FBW7 as a GSK3β-dependent E3 ligase for EglN2 relevant to breast tumorigenesis, multiplying the routes controlling PHD1 stability.","evidence":"FBW7 overexpression/knockdown, GSK3β inhibition, stability assays, Co-IP, and transgenic mouse model","pmids":["28036276"],"confidence":"Medium","gaps":["Phosphodegron priming sites not mapped","Interplay with SPOP/MDM2 unresolved"]},{"year":2017,"claim":"Provided a structural view of the PHD1 active site, defining a monodentate iron-coordinating inhibitor binding mode and an Asn315 hydrogen-bond contact.","evidence":"X-ray crystallography of PHD1-inhibitor complex and structure-activity analysis","pmids":["28594552"],"confidence":"Medium","gaps":["No substrate-bound structure","Basis of substrate selectivity not addressed structurally"]},{"year":2020,"claim":"Established a hydroxylation-independent scaffolding role coupling PHD1 to nutrient signaling: PHD1 stabilizes leucyl tRNA synthetase to sustain leucine-driven mTORC1 and muscle mass.","evidence":"PHD1-LRS Co-IP, catalytic-dead mutant, PHD1KO mice, leucine-specific mTORC1 assays, and human muscle biopsies","pmids":["31924757"],"confidence":"High","gaps":["Structural basis of PHD1-LRS protection undefined","Mechanism linking oxygen/amino-acid depletion to the interaction unresolved"]},{"year":2021,"claim":"Added MDM2 as an E3 ligase mediating K48-linked ubiquitination of EGLN2 via its N-terminus, further defining the proteostatic network governing PHD1.","evidence":"EGLN2-MDM2 Co-IP, K48-linkage ubiquitination assay, stability assays, and domain mapping","pmids":["34687132"],"confidence":"Medium","gaps":["Physiological/cell-context where MDM2 dominates unclear","Relationship to SPOP and FBW7 pathways untested"]},{"year":2023,"claim":"Linked PHD1 to bone biology, showing alpha-ketoglutarate suppresses RANKL-induced osteoclastogenesis through PHD1-dependent NF-κB inhibition.","evidence":"Isoform-specific siRNA, NF-κB reporter, osteoclast differentiation assay, and DMOG treatment","pmids":["36771407"],"confidence":"Medium","gaps":["Direct PHD1 substrate in NF-κB pathway not identified","Whether catalytic activity is required not tested here"]},{"year":2024,"claim":"Defined PHD1 control of autophagy, showing Beclin1 Pro54 hydroxylation enables VHL binding that blocks Beclin1-VPS34 association with ATG14L to inhibit autophagy initiation.","evidence":"In vitro hydroxylation, VHL-Beclin1 Co-IP, P54A mutagenesis, complex-assembly assays, autophagy flux, and xenografts","pmids":["38360997"],"confidence":"High","gaps":["Oxygen-tension dependence of this regulation under physiology not fully defined","Crosstalk with PHD1's metabolic roles unresolved"]},{"year":2024,"claim":"Implicated EGLN2 in neurodegeneration, showing its loss protects motor neurons in ALS models and restores STING-mediated astrocytic interferon responses.","evidence":"Egln2 knockout/ASO knockdown in zebrafish and mouse ALS models, snRNA-seq, and patient iPSC-astrocyte experiments","pmids":["39255062"],"confidence":"Medium","gaps":["Direct PHD1 substrate in the STING/interferon axis unidentified","Catalytic dependence of the effect untested"]},{"year":2025,"claim":"Extended PHD1's mitotic role, showing RepoMan/CDCA2 Pro604 hydroxylation governs RepoMan-PP2A-B56γ interaction and faithful chromosome segregation.","evidence":"MS site identification, isoform-specific siRNA, P604A mutagenesis, PP2A-B56γ Co-IP, H3T3 phospho-imaging, and live-cell mitosis imaging (preprint)","pmids":["bio_10.1101_2025.05.06.652400"],"confidence":"Medium","gaps":["Preprint not yet peer-reviewed","Integration with Cep192-based mitotic control unresolved"]},{"year":2025,"claim":"Added a catalysis-dependent route by which PHD1/PHD2 lower IKKα/β levels and dampen NF-κB target expression, complementing the osteoclast NF-κB findings.","evidence":"PHD-IKKα/β Co-IP, active-site mutants, IL-1β mRNA measurement, and IKK protein-level assays","pmids":["40024754"],"confidence":"Medium","gaps":["Whether IKKα/β are direct hydroxylation substrates not shown","PHD1 vs PHD2 relative contribution unresolved"]},{"year":null,"claim":"How CDK/PKC phosphorylation, multiple competing E3 ligases, and oxygen/metabolite levels are integrated to choose among PHD1's many catalytic and non-catalytic substrates in a given cell remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model of substrate prioritization","No substrate-bound structures to explain selectivity","Tissue-specific dominant substrates not defined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016491","term_label":"oxidoreductase activity","supporting_discovery_ids":[0,1,6]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,1,11,12,23,25]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,1]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[16]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[21,10]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[8]},{"term_id":"GO:0005730","term_label":"nucleolus","supporting_discovery_ids":[16]},{"term_id":"GO:0005815","term_label":"microtubule organizing center","supporting_discovery_ids":[11]}],"pathway":[{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[0,2,18]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[11,15,25]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[23]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[5,16,17]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[12,19,22,21]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[21,27,28]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[24,28]}],"complexes":["NRF1-PGC1α transcriptional complex"],"partners":["HIF1A","FOXO3","CEP192","BECN1","CDCA2","LARS","NRF1","MDM2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q96KS0","full_name":"Prolyl hydroxylase EGLN2","aliases":["Egl nine homolog 2","Estrogen-induced tag 6","EIT-6","HPH-3","Hypoxia-inducible factor prolyl hydroxylase 1","HIF-PH1","HIF-prolyl hydroxylase 1","HPH-1","Prolyl hydroxylase domain-containing protein 1","PHD1"],"length_aa":407,"mass_kda":43.6,"function":"Prolyl hydroxylase that mediates hydroxylation of proline residues in target proteins, such as ATF4, IKBKB, CEP192 and HIF1A (PubMed:11595184, PubMed:12039559, PubMed:15925519, PubMed:16509823, PubMed:17114296, PubMed:23932902). Target proteins are preferentially recognized via a LXXLAP motif (PubMed:11595184, PubMed:12039559, PubMed:15925519). Cellular oxygen sensor that catalyzes, under normoxic conditions, the post-translational formation of 4-hydroxyproline in hypoxia-inducible factor (HIF) alpha proteins (PubMed:11595184, PubMed:12039559, PubMed:12181324, PubMed:15925519, PubMed:19339211). Hydroxylates a specific proline found in each of the oxygen-dependent degradation (ODD) domains (N-terminal, NODD, and C-terminal, CODD) of HIF1A (PubMed:11595184, PubMed:12039559, PubMed:12181324, PubMed:15925519). Also hydroxylates HIF2A (PubMed:11595184, PubMed:12039559, PubMed:15925519). Has a preference for the CODD site for both HIF1A and HIF2A (PubMed:11595184, PubMed:12039559, PubMed:15925519). Hydroxylated HIFs are then targeted for proteasomal degradation via the von Hippel-Lindau ubiquitination complex (PubMed:11595184, PubMed:12039559, PubMed:15925519). Under hypoxic conditions, the hydroxylation reaction is attenuated allowing HIFs to escape degradation resulting in their translocation to the nucleus, heterodimerization with HIF1B, and increased expression of hypoxy-inducible genes (PubMed:11595184, PubMed:12039559, PubMed:15925519). EGLN2 is involved in regulating hypoxia tolerance and apoptosis in cardiac and skeletal muscle (PubMed:11595184, PubMed:12039559, PubMed:15925519). Also regulates susceptibility to normoxic oxidative neuronal death (PubMed:11595184, PubMed:12039559, PubMed:15925519). Links oxygen sensing to cell cycle and primary cilia formation by hydroxylating the critical centrosome component CEP192 which promotes its ubiquitination and subsequent proteasomal degradation (PubMed:23932902). Hydroxylates IKBKB, mediating NF-kappa-B activation in hypoxic conditions (PubMed:17114296). Also mediates hydroxylation of ATF4, leading to decreased protein stability of ATF4 (By similarity)","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q96KS0/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/EGLN2","classification":"Not Classified","n_dependent_lines":90,"n_total_lines":1208,"dependency_fraction":0.07450331125827815},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/EGLN2","total_profiled":1310},"omim":[{"mim_id":"606424","title":"EGL9 FAMILY HYPOXIA-INDUCIBLE FACTOR 2; EGLN2","url":"https://www.omim.org/entry/606424"},{"mim_id":"604556","title":"DUAL-SPECIFICITY TYROSINE PHOSPHORYLATION-REGULATED KINASE 1B; DYRK1B","url":"https://www.omim.org/entry/604556"},{"mim_id":"603349","title":"ENDOTHELIAL PAS DOMAIN PROTEIN 1; EPAS1","url":"https://www.omim.org/entry/603349"},{"mim_id":"600855","title":"DUAL-SPECIFICITY TYROSINE PHOSPHORYLATION-REGULATED KINASE 1A; DYRK1A","url":"https://www.omim.org/entry/600855"},{"mim_id":"600386","title":"INHIBITOR OF DNA BINDING 2; ID2","url":"https://www.omim.org/entry/600386"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"testis","ntpm":223.9}],"url":"https://www.proteinatlas.org/search/EGLN2"},"hgnc":{"alias_symbol":["PHD1","HIFPH1"],"prev_symbol":[]},"alphafold":{"accession":"Q96KS0","domains":[{"cath_id":"2.60.120.620","chopping":"172-391","consensus_level":"high","plddt":92.4935,"start":172,"end":391}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q96KS0","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q96KS0-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q96KS0-F1-predicted_aligned_error_v6.png","plddt_mean":67.81},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=EGLN2","jax_strain_url":"https://www.jax.org/strain/search?query=EGLN2"},"sequence":{"accession":"Q96KS0","fasta_url":"https://rest.uniprot.org/uniprotkb/Q96KS0.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q96KS0/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q96KS0"}},"corpus_meta":[{"pmid":"15247232","id":"PMC_15247232","title":"Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15247232","citation_count":905,"is_preprint":false},{"pmid":"18176562","id":"PMC_18176562","title":"Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism.","date":"2008","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18176562","citation_count":392,"is_preprint":false},{"pmid":"12181324","id":"PMC_12181324","title":"Sequence determinants in hypoxia-inducible factor-1alpha for hydroxylation by the prolyl hydroxylases PHD1, PHD2, and PHD3.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12181324","citation_count":258,"is_preprint":false},{"pmid":"31924757","id":"PMC_31924757","title":"PHD1 controls muscle mTORC1 in a hydroxylation-independent manner by stabilizing leucyl tRNA synthetase.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31924757","citation_count":255,"is_preprint":false},{"pmid":"8114741","id":"PMC_8114741","title":"Induction of pseudohyphal growth by overexpression of PHD1, a Saccharomyces cerevisiae gene related to transcriptional regulators of fungal development.","date":"1994","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8114741","citation_count":221,"is_preprint":false},{"pmid":"19878873","id":"PMC_19878873","title":"Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase.","date":"2009","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/19878873","citation_count":117,"is_preprint":false},{"pmid":"24990963","id":"PMC_24990963","title":"Prolyl hydroxylation by EglN2 destabilizes FOXO3a by blocking its interaction with the USP9x deubiquitinase.","date":"2014","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/24990963","citation_count":112,"is_preprint":false},{"pmid":"19818783","id":"PMC_19818783","title":"Loss or silencing of the PHD1 prolyl hydroxylase protects livers of mice against ischemia/reperfusion injury.","date":"2009","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/19818783","citation_count":109,"is_preprint":false},{"pmid":"25263965","id":"PMC_25263965","title":"Germ-line PHD1 and PHD2 mutations detected in patients with pheochromocytoma/paraganglioma-polycythemia.","date":"2014","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/25263965","citation_count":108,"is_preprint":false},{"pmid":"12039559","id":"PMC_12039559","title":"The use of dioxygen by HIF prolyl hydroxylase (PHD1).","date":"2002","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/12039559","citation_count":98,"is_preprint":false},{"pmid":"14695194","id":"PMC_14695194","title":"Expression of prolyl-hydroxylase-1 (PHD1/EGLN2) suppresses hypoxia inducible factor-1alpha activation and inhibits tumor growth.","date":"2003","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/14695194","citation_count":91,"is_preprint":false},{"pmid":"18927305","id":"PMC_18927305","title":"Overexpression of the oxygen sensors PHD-1, PHD-2, PHD-3, and FIH Is associated with tumor aggressiveness in pancreatic endocrine tumors.","date":"2008","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/18927305","citation_count":78,"is_preprint":false},{"pmid":"26774962","id":"PMC_26774962","title":"Deletion or Inhibition of the Oxygen Sensor PHD1 Protects against Ischemic Stroke via Reprogramming of Neuronal Metabolism.","date":"2016","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/26774962","citation_count":76,"is_preprint":false},{"pmid":"16324198","id":"PMC_16324198","title":"Use of novel monoclonal antibodies to determine the expression and distribution of the hypoxia regulatory factors PHD-1, PHD-2, PHD-3 and FIH in normal and neoplastic human tissues.","date":"2005","source":"Histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/16324198","citation_count":76,"is_preprint":false},{"pmid":"23932902","id":"PMC_23932902","title":"PHD1 links cell-cycle progression to oxygen sensing through hydroxylation of the centrosomal protein Cep192.","date":"2013","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/23932902","citation_count":74,"is_preprint":false},{"pmid":"26492917","id":"PMC_26492917","title":"EglN2 associates with the NRF1-PGC1α complex and controls mitochondrial function in breast cancer.","date":"2015","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/26492917","citation_count":70,"is_preprint":false},{"pmid":"23077531","id":"PMC_23077531","title":"Exploring PHD fingers and H3K4me0 interactions with molecular dynamics simulations and binding free energy calculations: AIRE-PHD1, a comparative study.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23077531","citation_count":70,"is_preprint":false},{"pmid":"21083501","id":"PMC_21083501","title":"Disruption of hypoxia-inducible transcription factor-prolyl hydroxylase domain-1 (PHD-1-/-) attenuates ex vivo myocardial ischemia/reperfusion injury through hypoxia-inducible factor-1α transcription factor and its target genes in mice.","date":"2011","source":"Antioxidants & redox signaling","url":"https://pubmed.ncbi.nlm.nih.gov/21083501","citation_count":68,"is_preprint":false},{"pmid":"21552514","id":"PMC_21552514","title":"The stress response factors Yap6, Cin5, Phd1, and Skn7 direct targeting of the conserved co-repressor Tup1-Ssn6 in S. cerevisiae.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21552514","citation_count":67,"is_preprint":false},{"pmid":"18773095","id":"PMC_18773095","title":"Somatic pairing of chromosome 19 in renal oncocytoma is associated with deregulated EGLN2-mediated [corrected] oxygen-sensing response.","date":"2008","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18773095","citation_count":55,"is_preprint":false},{"pmid":"26290450","id":"PMC_26290450","title":"PHD1 regulates p53-mediated colorectal cancer chemoresistance.","date":"2015","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26290450","citation_count":47,"is_preprint":false},{"pmid":"24195777","id":"PMC_24195777","title":"Expression and DNA methylation levels of prolyl hydroxylases PHD1, PHD2, PHD3 and asparaginyl hydroxylase FIH in colorectal cancer.","date":"2013","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24195777","citation_count":44,"is_preprint":false},{"pmid":"16509823","id":"PMC_16509823","title":"Characterization of different isoforms of the HIF prolyl hydroxylase PHD1 generated by alternative initiation.","date":"2006","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/16509823","citation_count":43,"is_preprint":false},{"pmid":"28089830","id":"PMC_28089830","title":"Tumor suppressor SPOP ubiquitinates and degrades EglN2 to compromise growth of prostate cancer cells.","date":"2017","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/28089830","citation_count":41,"is_preprint":false},{"pmid":"30665327","id":"PMC_30665327","title":"EGLN2 DNA methylation and expression interact with HIF1A to affect survival of early-stage NSCLC.","date":"2019","source":"Epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/30665327","citation_count":35,"is_preprint":false},{"pmid":"31944416","id":"PMC_31944416","title":"Mucosal inflammation downregulates PHD1 expression promoting a barrier-protective HIF-1α response in ulcerative colitis patients.","date":"2020","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/31944416","citation_count":35,"is_preprint":false},{"pmid":"27263528","id":"PMC_27263528","title":"Docetaxel induced-JNK2/PHD1 signaling pathway increases degradation of HIF-1α and causes cancer cell death under hypoxia.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27263528","citation_count":35,"is_preprint":false},{"pmid":"22124158","id":"PMC_22124158","title":"Cdk8 regulates stability of the transcription factor Phd1 to control pseudohyphal differentiation of Saccharomyces cerevisiae.","date":"2011","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/22124158","citation_count":35,"is_preprint":false},{"pmid":"20497244","id":"PMC_20497244","title":"Expression of key hypoxia sensing prolyl-hydroxylases PHD1, -2 and -3 in pancreaticobiliary cancer.","date":"2010","source":"Histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/20497244","citation_count":34,"is_preprint":false},{"pmid":"19631610","id":"PMC_19631610","title":"Cellular oxygen sensing: Importins and exportins are mediators of intracellular localisation of prolyl-4-hydroxylases PHD1 and PHD2.","date":"2009","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/19631610","citation_count":34,"is_preprint":false},{"pmid":"25446011","id":"PMC_25446011","title":"Deletion of prolyl hydroxylase domain proteins (PHD1, PHD3) stabilizes hypoxia inducible factor-1 alpha, promotes neovascularization, and improves perfusion in a murine model of hind-limb ischemia.","date":"2014","source":"Microvascular research","url":"https://pubmed.ncbi.nlm.nih.gov/25446011","citation_count":32,"is_preprint":false},{"pmid":"24045616","id":"PMC_24045616","title":"Variants in two adjacent genes, EGLN2 and CYP2A6, influence smoking behavior related to disease risk via different mechanisms.","date":"2013","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24045616","citation_count":28,"is_preprint":false},{"pmid":"21951999","id":"PMC_21951999","title":"PHD1 interacts with ATF4 and negatively regulates its transcriptional activity without prolyl hydroxylation.","date":"2011","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/21951999","citation_count":28,"is_preprint":false},{"pmid":"22961008","id":"PMC_22961008","title":"Deficiency of the oxygen sensor PHD1 augments liver regeneration after partial hepatectomy.","date":"2012","source":"Langenbeck's archives of surgery","url":"https://pubmed.ncbi.nlm.nih.gov/22961008","citation_count":27,"is_preprint":false},{"pmid":"27094951","id":"PMC_27094951","title":"Hypoxia-inducible factor prolyl hydroxylase 1 (PHD1) deficiency promotes hepatic steatosis and liver-specific insulin resistance in mice.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27094951","citation_count":26,"is_preprint":false},{"pmid":"30843652","id":"PMC_30843652","title":"Overexpression of long non-coding RNA NORAD promotes invasion and migration in malignant melanoma via regulating the MIR-205-EGLN2 pathway.","date":"2019","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30843652","citation_count":24,"is_preprint":false},{"pmid":"32558530","id":"PMC_32558530","title":"Long non-coding RNA LINC00662 promotes proliferation and migration of breast cancer cells via regulating the miR-497-5p/EglN2 axis.","date":"2020","source":"Acta biochimica Polonica","url":"https://pubmed.ncbi.nlm.nih.gov/32558530","citation_count":23,"is_preprint":false},{"pmid":"18187257","id":"PMC_18187257","title":"Expression of prolyl-hydroxylases PHD-1, 2 and 3 and of the asparagine hydroxylase FIH in non-small cell lung cancer relates to an activated HIF pathway.","date":"2008","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/18187257","citation_count":22,"is_preprint":false},{"pmid":"38360997","id":"PMC_38360997","title":"VHL suppresses autophagy and tumor growth through PHD1-dependent Beclin1 hydroxylation.","date":"2024","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/38360997","citation_count":20,"is_preprint":false},{"pmid":"28036276","id":"PMC_28036276","title":"EglN2 contributes to triple negative breast tumorigenesis by functioning as a substrate for the FBW7 tumor suppressor.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28036276","citation_count":20,"is_preprint":false},{"pmid":"28594552","id":"PMC_28594552","title":"1,2,4-Triazolo-[1,5-a]pyridine HIF Prolylhydroxylase Domain-1 (PHD-1) Inhibitors With a Novel Monodentate Binding Interaction.","date":"2017","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28594552","citation_count":20,"is_preprint":false},{"pmid":"34687132","id":"PMC_34687132","title":"LncRNA MIAT enhances cerebral ischaemia/reperfusion injury in rat model via interacting with EGLN2 and reduces its ubiquitin-mediated degradation.","date":"2021","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34687132","citation_count":19,"is_preprint":false},{"pmid":"20727020","id":"PMC_20727020","title":"DNA methylation analysis of the HIF-1α prolyl hydroxylase domain genes PHD1, PHD2, PHD3 and the factor inhibiting HIF gene FIH in invasive breast carcinomas.","date":"2010","source":"Histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/20727020","citation_count":17,"is_preprint":false},{"pmid":"9781677","id":"PMC_9781677","title":"phd1+, a histone deacetylase gene of Schizosaccharomyces pombe, is required for the meiotic cell cycle and resistance to trichostatin A.","date":"1998","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/9781677","citation_count":16,"is_preprint":false},{"pmid":"26644182","id":"PMC_26644182","title":"CDK-dependent phosphorylation of PHD1 on serine 130 alters its substrate preference in cells.","date":"2015","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/26644182","citation_count":15,"is_preprint":false},{"pmid":"15178343","id":"PMC_15178343","title":"Hypoxia-dependent regulation of PHD1: cloning and characterization of the human PHD1/EGLN2 gene promoter.","date":"2004","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/15178343","citation_count":13,"is_preprint":false},{"pmid":"38634741","id":"PMC_38634741","title":"Hypoxia-mediated attenuation of EGLN2 inhibition of the NF-κB signaling pathway leads to the formation of a loop between HIF-1α and MUC1-C promoting chemoresistance in bladder cancer.","date":"2024","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/38634741","citation_count":13,"is_preprint":false},{"pmid":"28539891","id":"PMC_28539891","title":"Double Knockdown of PHD1 and Keap1 Attenuated Hypoxia-Induced Injuries in Hepatocytes.","date":"2017","source":"Frontiers in physiology","url":"https://pubmed.ncbi.nlm.nih.gov/28539891","citation_count":13,"is_preprint":false},{"pmid":"36771407","id":"PMC_36771407","title":"Elevation of Intracellular Alpha-Ketoglutarate Levels Inhibits Osteoclastogenesis by Suppressing the NF-κB Signaling Pathway in a PHD1-Dependent Manner.","date":"2023","source":"Nutrients","url":"https://pubmed.ncbi.nlm.nih.gov/36771407","citation_count":13,"is_preprint":false},{"pmid":"33621062","id":"PMC_33621062","title":"Recognition of Histone H3 Methylation States by the PHD1 Domain of Histone Demethylase KDM5A.","date":"2021","source":"ACS chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/33621062","citation_count":12,"is_preprint":false},{"pmid":"23263989","id":"PMC_23263989","title":"The conserved PHD1-PHD2 domain of ZFP-1/AF10 is a discrete functional module essential for viability in Caenorhabditis elegans.","date":"2012","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/23263989","citation_count":12,"is_preprint":false},{"pmid":"24894671","id":"PMC_24894671","title":"Polymorphism in PHD1 gene and risk of non-small cell lung cancer in a Chinese population.","date":"2014","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24894671","citation_count":10,"is_preprint":false},{"pmid":"25609945","id":"PMC_25609945","title":"EGLN2 and RNF150 genetic variants are associated with chronic obstructive pulmonary disease risk in the Chinese population.","date":"2015","source":"International journal of chronic obstructive pulmonary disease","url":"https://pubmed.ncbi.nlm.nih.gov/25609945","citation_count":9,"is_preprint":false},{"pmid":"36436490","id":"PMC_36436490","title":"Modulation of miR-205/ EGLN2 by rosuvastatin mitigates colistin-induced nephrotoxicity in rats: Involvement of ATF4/ CHOP and Nrf2 pathways.","date":"2022","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/36436490","citation_count":9,"is_preprint":false},{"pmid":"28218358","id":"PMC_28218358","title":"An insertion/deletion polymorphism within the promoter of EGLN2 is associated with susceptibility to colorectal cancer.","date":"2017","source":"The International journal of biological markers","url":"https://pubmed.ncbi.nlm.nih.gov/28218358","citation_count":9,"is_preprint":false},{"pmid":"39255062","id":"PMC_39255062","title":"Targeting EGLN2/PHD1 protects motor neurons and normalizes the astrocytic interferon response.","date":"2024","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/39255062","citation_count":8,"is_preprint":false},{"pmid":"22645445","id":"PMC_22645445","title":"Molecular cloning of phd1 and comparative analysis of phd1, 2, and 3 expression in Xenopus laevis.","date":"2012","source":"TheScientificWorldJournal","url":"https://pubmed.ncbi.nlm.nih.gov/22645445","citation_count":8,"is_preprint":false},{"pmid":"18710826","id":"PMC_18710826","title":"Expression, purification and characterization of human PHD1 in Escherichia coli.","date":"2008","source":"Journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18710826","citation_count":7,"is_preprint":false},{"pmid":"38509356","id":"PMC_38509356","title":"PHD1-3 oxygen sensors in vivo-lessons learned from gene deletions.","date":"2024","source":"Pflugers Archiv : European journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/38509356","citation_count":6,"is_preprint":false},{"pmid":"36676055","id":"PMC_36676055","title":"Lack of Skeletal Effects in Mice with Targeted Disruptionof Prolyl Hydroxylase Domain 1 (Phd1) Gene Expressed in Chondrocytes.","date":"2022","source":"Life (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/36676055","citation_count":6,"is_preprint":false},{"pmid":"27308620","id":"PMC_27308620","title":"EglN2 positively regulates mitochondrial function in breast cancer.","date":"2015","source":"Molecular & cellular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/27308620","citation_count":6,"is_preprint":false},{"pmid":"26303495","id":"PMC_26303495","title":"Augmented 5-HT Secretion in Pulmonary Neuroepithelial Bodies from PHD1 Null Mice.","date":"2015","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/26303495","citation_count":6,"is_preprint":false},{"pmid":"30086363","id":"PMC_30086363","title":"The molecular characterization, expression pattern and alternative initiation of Megalobrama amblycephala Hif prolyl hydroxylase Phd1.","date":"2018","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/30086363","citation_count":5,"is_preprint":false},{"pmid":"29899699","id":"PMC_29899699","title":"Effects of Simultaneous Downregulation of PHD1 and Keap1 on Prevention and Reversal of Liver Fibrosis in Mice.","date":"2018","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/29899699","citation_count":5,"is_preprint":false},{"pmid":"39647834","id":"PMC_39647834","title":"YAP1 Overexpression Enhances the Aerobic Glycolysis Process via Suppression of EGLN2 in Pancreatic Ductal Adenocarcinoma.","date":"2024","source":"The journal of gene medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39647834","citation_count":4,"is_preprint":false},{"pmid":"33314922","id":"PMC_33314922","title":"Exploring the Ligand Preferences of the PHD1 Domain of Histone Demethylase KDM5A Reveals Tolerance for Modifications of the Q5 Residue of Histone 3.","date":"2020","source":"ACS chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/33314922","citation_count":3,"is_preprint":false},{"pmid":"40958522","id":"PMC_40958522","title":"EGLN2 attenuates ovarian cancer malignancy via ferroptosis activation.","date":"2025","source":"Neoplasma","url":"https://pubmed.ncbi.nlm.nih.gov/40958522","citation_count":2,"is_preprint":false},{"pmid":"39184054","id":"PMC_39184054","title":"Mass Spectrometry-Based Protein Footprinting Defines the Binding Pocket of Crotonylated H3K14 in the PHD1 Domain of BAF45D within the BAF Chromatin Remodeling Complex.","date":"2024","source":"ACS bio & med chem Au","url":"https://pubmed.ncbi.nlm.nih.gov/39184054","citation_count":2,"is_preprint":false},{"pmid":"39162481","id":"PMC_39162481","title":"Zebrafish phd1 enhances mavs-mediated antiviral responses in a hydroxylation-independent manner.","date":"2024","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/39162481","citation_count":1,"is_preprint":false},{"pmid":"41082962","id":"PMC_41082962","title":"Hypoxia-driven ferroptosis escape mediates lung injury induced by nickel-refining fumes via oxygen-sensing signaling PHD1/HIF-1α.","date":"2025","source":"Environmental pollution (Barking, Essex : 1987)","url":"https://pubmed.ncbi.nlm.nih.gov/41082962","citation_count":1,"is_preprint":false},{"pmid":"38456036","id":"PMC_38456036","title":"Identifying ligands for the PHD1 finger of KDM5A through high-throughput screening.","date":"2023","source":"RSC chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/38456036","citation_count":1,"is_preprint":false},{"pmid":"40024754","id":"PMC_40024754","title":"Prolyl hydroxylase domain enzymes (isoforms 1-3, PHD1-3), but not factor-inhibiting HIF-1 (FIH-1), interact with the IKK complex and attenuate LPS-activated NF-kappa-B.","date":"2025","source":"The Journal of toxicological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/40024754","citation_count":1,"is_preprint":false},{"pmid":"41643377","id":"PMC_41643377","title":"Exosomal lncRNA ENSSSCG00000049656 regulates porcine oocyte maturation via the ssc-miR-500-3p/EGLN2 axis.","date":"2026","source":"Theriogenology","url":"https://pubmed.ncbi.nlm.nih.gov/41643377","citation_count":0,"is_preprint":false},{"pmid":"42126822","id":"PMC_42126822","title":"Targeted Degradation of Prolyl Hydroxylase Domain Enzyme 1 (PHD1) as a Novel Therapeutic Strategy for Acetaminophen-Induced Acute Liver Injury.","date":"2026","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/42126822","citation_count":0,"is_preprint":false},{"pmid":"42127541","id":"PMC_42127541","title":"Chrysin reshapes ferroptosis sensitivity to reverse nickel refining fumes-induced lung injury via the miR-210/ANGPTL4 signaling axis mediated by the PHD1/HIF-1α pathway.","date":"2026","source":"Ecotoxicology and environmental safety","url":"https://pubmed.ncbi.nlm.nih.gov/42127541","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.05.06.652400","title":"PHD1-dependent hydroxylation of RepoMan (CDCA2) on P604 modulates the control of mitotic progression","date":"2025-05-07","source":"bioRxiv","url":"https://doi.org/10.1101/2025.05.06.652400","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.10.11.681841","title":"Bioinformatic inference of the exercise-responsive control of p70 S6 kinase through  <i>RPS6KB1</i>  expression","date":"2025-10-13","source":"bioRxiv","url":"https://doi.org/10.1101/2025.10.11.681841","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.01.15.633218","title":"Myositis-specific autoantibodies recognizing Mi2 also target the autoimmune regulator (AIRE) protein at a shared PHD-zinc finger","date":"2025-01-19","source":"bioRxiv","url":"https://doi.org/10.1101/2025.01.15.633218","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.04.21.649850","title":"Endothelial Prolyl Hydroxylase 3 Mitigates Maladaptive Inflammation to Promote Post-Ischemic Kidney Repair","date":"2025-04-22","source":"bioRxiv","url":"https://doi.org/10.1101/2025.04.21.649850","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":41581,"output_tokens":7747,"usd":0.120474,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17475,"output_tokens":7916,"usd":0.142638,"stage2_stop_reason":"end_turn"},"total_usd":0.263112,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2002,\n      \"finding\": \"PHD1 (EGLN2) is an iron(II)- and 2-oxoglutarate-dependent oxygenase that hydroxylates proline residues in HIF-1α; mutation of the arginine proposed to bind 2-oxoglutarate and of the 2His-1-carboxylate iron(II) binding motif dramatically reduces activity; the oxygen of the product alcohol derives >95% from dioxygen.\",\n      \"method\": \"In vitro enzymatic assay with active-site mutagenesis; isotope labeling to trace oxygen source\",\n      \"journal\": \"Bioorganic & medicinal chemistry letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct in vitro enzymatic assay with mutagenesis of active-site residues and isotope-tracing; single paper but multiple orthogonal methods\",\n      \"pmids\": [\"12039559\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"PHD1, PHD2, and PHD3 hydroxylate specific prolines in HIF-1α within the LXXLAP motif; PHD2 has the highest specific activity toward the primary hydroxylation site; the hydroxylacceptor proline itself is the only obligatory residue in the motif, with mutations tolerated at the -5, -2, and -1 positions.\",\n      \"method\": \"In vitro prolyl hydroxylation assay with systematic LXXLAP motif mutants; specific activity comparisons across PHD isoforms\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstituted in vitro enzymatic assay with systematic mutagenesis; single lab but multiple mutants tested with quantitative comparisons\",\n      \"pmids\": [\"12181324\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"PHD1, PHD2, and PHD3 each contribute in a non-redundant manner to the regulation of both HIF-1α and HIF-2α; the relative contribution of each PHD isoform depends on its cellular abundance; isoforms show specificity for different prolyl hydroxylation sites within HIF-α subunits and a degree of selectivity between HIF-1α and HIF-2α.\",\n      \"method\": \"siRNA knockdown of each PHD isoform individually in multiple cell types; measurement of HIF-α levels and site-specific hydroxylation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — siRNA loss-of-function in multiple cell types with quantitative readouts; replicated across isoforms and cell lines in single study\",\n      \"pmids\": [\"15247232\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Ectopic expression of PHD1 (EGLN2) suppresses HIF-1α accumulation and VEGF secretion under hypoxia-mimetic conditions and inhibits tumor growth in vivo, associated with increased necrosis and decreased microvessel density.\",\n      \"method\": \"Overexpression of mPHD1 in colon carcinoma cells; xenograft tumor model in nude mice; immunostaining for HIF-1α and microvessel density\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain-of-function with defined cellular and in vivo phenotypic readouts; single lab, two orthogonal readouts (HIF suppression + tumor growth)\",\n      \"pmids\": [\"14695194\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"PHD1 exists as two isoforms generated by alternative translational initiation; both isoforms are biologically active with similar HIF prolyl hydroxylase activity but differ in their responses to estrogen, cell confluence, and proteasomal inhibition, and differ markedly in protein stability. Both isoforms have the potential to interact with Siah ubiquitin ligase family members, though genetic studies indicated other proteolytic mechanisms control their stability under examined conditions.\",\n      \"method\": \"Characterization of isoforms by mutagenesis of start codons; HIF prolyl hydroxylase activity assays; protein stability assays; co-immunoprecipitation with Siah proteins\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple assays (activity, stability, interaction) in single lab; direct demonstration of alternative initiation and functional equivalence\",\n      \"pmids\": [\"16509823\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Loss of Phd1 lowers oxygen consumption in skeletal muscle by reprogramming glucose metabolism from oxidative to anaerobic ATP production through activation of a PPARα pathway; this metabolic adaptation provides acute protection of myofibers against lethal ischemia; hypoxia tolerance relies primarily on Hif-2α and is not due to HIF-dependent angiogenesis, erythropoiesis, or vasodilation, but to reduced oxidative stress preserving mitochondrial respiration.\",\n      \"method\": \"Phd1 knockout mice; metabolic profiling; genetic epistasis with Hif-2α; histology of ischemic muscle; measurement of oxidative stress\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout with comprehensive metabolic profiling, epistasis analysis, and multiple orthogonal phenotypic readouts; replicated across conditions\",\n      \"pmids\": [\"18176562\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Human PHD1 purified from E. coli is an Fe2+- and 2-oxoglutarate-dependent enzyme with EC50 for Fe2+ of 0.64 μM; it is phosphorylated in vitro by protein kinase Cα at Ser-132, Ser-226, and Ser-234; mutation of Ser-132 or Ser-234 to Asp/Glu diminishes enzymatic activity to 25–60%, whereas mutation of Ser-226 has little effect.\",\n      \"method\": \"Recombinant protein purification; in vitro kinase assay with PKCα, PKA, CKI/II, Erk2; site-directed mutagenesis; prolyl hydroxylase activity assay\",\n      \"journal\": \"Journal of biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstituted in vitro enzymatic system with mutagenesis of phosphorylation sites; multiple kinases tested; activity consequences directly measured\",\n      \"pmids\": [\"18710826\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"EGLN2 overexpression in renal oncocytoma increases ubiquitin-mediated destruction of HIF and concomitantly suppresses the expression of HIF-target genes including the pro-death BNIP3L gene.\",\n      \"method\": \"Gene expression profiling; functional overexpression studies in renal oncocytoma cells; ubiquitination assays for HIF\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — functional overexpression with HIF ubiquitination readout; single study, limited mechanistic depth in abstract\",\n      \"pmids\": [\"18773095\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Nuclear import of PHD1 occurs in an importin α/β-dependent manner and relies on a nuclear localization signal (NLS); PHD1 is located exclusively in the nucleus, in contrast to PHD2 which cycles between nucleus and cytoplasm.\",\n      \"method\": \"Subcellular fractionation; importin α/β inhibition; fluorescence microscopy; NLS mutagenesis\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization experiments with mechanistic follow-up (NLS identification, importin dependence); single lab\",\n      \"pmids\": [\"19631610\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"EglN2 (PHD1) is estrogen-inducible in breast carcinoma cells; EglN2 inactivation decreases Cyclin D1 levels and suppresses mammary gland proliferation in vivo in a HIF-independent manner; loss of EglN2 catalytic activity inhibits estrogen-dependent breast cancer tumorigenesis, rescued by exogenous Cyclin D1.\",\n      \"method\": \"EglN2 knockout mice; siRNA knockdown in breast cancer cells; mammary gland histology; Cyclin D1 rescue experiment; catalytic mutant studies\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo knockout phenotype, genetic rescue with Cyclin D1, catalytic activity requirement established; multiple orthogonal approaches in single study\",\n      \"pmids\": [\"19878873\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"PHD1 interacts with ATF4 (but not PHD2) through the central region of ATF4; co-expression of PHD1 stabilizes ATF4 (opposite to PHD3 which destabilizes it); PHD1 represses the transcriptional activity of ATF4; ATF4 does not serve as a prolyl hydroxylation substrate of PHD1 (negative finding for hydroxylation); the interaction and transcriptional repression occur without prolyl hydroxylation of ATF4.\",\n      \"method\": \"Co-immunoprecipitation; in vitro prolyl hydroxylation assay; reporter assay for ATF4 transcriptional activity; protein stability assays; proline-to-alanine mutagenesis of ATF4\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP, in vitro hydroxylation assay confirming negative result, reporter assay; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"21951999\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"PHD1 is required for centrosome duplication and maturation through hydroxylation of the centrosomal protein Cep192 on proline 1717; this hydroxylation promotes binding of the E3 ubiquitin ligase SCF(Skp2), which ubiquitinates Cep192 and targets it for proteasomal degradation; PHD1 is also required for primary cilia formation.\",\n      \"method\": \"PHD1 loss-of-function; mass spectrometry identification of Cep192 as substrate; site-directed mutagenesis of Cep192 P1717; co-immunoprecipitation with SCF(Skp2); ubiquitination assay; centrosome/cilia imaging\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct identification of hydroxylation site by MS, mutagenesis confirming functional requirement, biochemical reconstitution of SCF(Skp2) binding, multiple cellular readouts\",\n      \"pmids\": [\"23932902\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"EglN2 hydroxylates FOXO3a on two specific prolyl residues in vitro and in vivo; hydroxylation of these sites prevents binding of the USP9x deubiquitinase, thereby promoting proteasomal degradation of FOXO3a; failure to hydroxylate FOXO3a promotes its accumulation, which suppresses Cyclin D1 transcription (because FOXO transcription factors can repress Cyclin D1).\",\n      \"method\": \"In vitro prolyl hydroxylation assay; mass spectrometry identification of hydroxylation sites; co-immunoprecipitation of FOXO3a with USP9x; protein stability assays; Cyclin D1 reporter/expression analysis\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro hydroxylation assay with site identification, mechanistic link to USP9x binding, downstream Cyclin D1 regulation; multiple orthogonal methods in single study\",\n      \"pmids\": [\"24990963\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"A germline loss-of-function mutation in PHD1 causes reduced protein stability and compromised catalytic activity, associated with pheochromocytoma/paraganglioma and polycythemia, with inappropriate hypersensitivity of erythroid progenitors to EPO.\",\n      \"method\": \"Sequencing of patient samples; protein stability assays; in vitro catalytic activity measurement; erythroid progenitor EPO sensitivity assay\",\n      \"journal\": \"Journal of molecular medicine (Berlin, Germany)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — catalytic activity and stability directly measured in patient mutant; single study with limited mechanistic follow-up\",\n      \"pmids\": [\"25263965\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PHD1 activity reinforces p53 binding to p38α kinase in a hydroxylation-dependent manner; following p53-p38α interaction and chemotherapeutic damage, p53 is phosphorylated at serine 15 and activated; active p53 interacts with the DNA helicase XPB to allow nucleotide excision repair; PHD1 knockdown (but not PHD2 or PHD3) prevents p53 activation upon chemotherapy in CRC cells.\",\n      \"method\": \"siRNA knockdown of PHD isoforms; co-immunoprecipitation of p53 with p38α; phospho-specific western blotting (p53 S15); interaction assay with XPB; mouse xenograft with 5-FU treatment\",\n      \"journal\": \"EMBO molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP, phospho-western, isoform-specific knockdown with clear phenotype; single lab, multiple methods\",\n      \"pmids\": [\"26290450\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PHD1 is phosphorylated by CDK2, CDK4, and CDK6 at serine 130; this phosphorylation fluctuates with the cell cycle and can be induced by oncogenic activation; S130 phosphorylation does not alter PHD1's intrinsic enzymatic activity but decreases its interaction with HIF1α (reducing PHD1 activity toward HIF1α) while increasing PHD1's activity toward Cep192.\",\n      \"method\": \"In vitro kinase assays with CDK2/4/6; phospho-specific antibody to pS130; cell cycle synchronization; co-immunoprecipitation of PHD1 with HIF1α; substrate activity assays toward HIF1α and Cep192\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay, mutagenesis, co-IP, and substrate activity assays; single lab but multiple orthogonal methods establishing mechanism\",\n      \"pmids\": [\"26644182\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"EglN2 associates with the NRF1-PGC1α complex on chromatin under hypoxic conditions and promotes transcription of ferredoxin reductase (FDXR); EglN2 depletion decreases mitochondrial respiration and mitochondrial DNA content in breast cancer cells in a HIF1/2α-independent manner.\",\n      \"method\": \"Co-immunoprecipitation of EglN2 with NRF1 and PGC1α; chromatin immunoprecipitation (ChIP); gene expression profiling; mitochondrial respiration measurements; mtDNA quantification; siRNA knockdown\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, ChIP, functional metabolic readouts; multiple orthogonal methods in single study establishing EglN2 as transcriptional co-activator\",\n      \"pmids\": [\"26492917\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"PHD1 deficiency in neurons reprograms glucose metabolism by enhancing flux through the oxidative pentose phosphate pathway (away from glycolysis), increasing redox buffering capacity to scavenge oxygen radicals; this provides neuroprotection against ischemia independently of collateral vessel network changes.\",\n      \"method\": \"PHD1 knockout mice; permanent brain ischemia model; metabolic flux analysis; ROS measurements; intracerebroventricular antisense oligonucleotide injection\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout with metabolic flux analysis and therapeutic antisense validation; multiple readouts and in vivo rescue\",\n      \"pmids\": [\"26774962\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Docetaxel activates PHD1 under hypoxic conditions through JNK2 signaling; activated PHD1 promotes polyubiquitination and proteasomal degradation of HIF-1α; pharmacological inhibition or siRNA knockdown of PHD1 prevents docetaxel-induced HIF-1α degradation and cancer cell death under hypoxia.\",\n      \"method\": \"JNK2 siRNA knockdown; PHD1 siRNA knockdown; pharmacological PHD1 inhibition; HIF-1α polyubiquitination assay; luciferase reporter for HIF-1 transcriptional activity; xenograft model\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA knockdown of JNK2 and PHD1 with mechanistic linkage, ubiquitination assay; single lab, multiple methods\",\n      \"pmids\": [\"27263528\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"The E3 ubiquitin ligase SPOP (Cullin 3-based complex) recognizes and ubiquitinates EglN2, targeting it for proteasomal degradation; androgen receptor (AR) transcriptionally upregulates EglN2; SPOP loss-of-function mutations or AR amplification (common in prostate cancer) accumulate EglN2 protein.\",\n      \"method\": \"Co-immunoprecipitation of SPOP and EglN2; ubiquitination assay; SPOP loss-of-function mutants; AR ChIP/transcription assays; in vivo tumor models\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP, ubiquitination assay, SPOP mutant analysis; single lab, multiple methods establishing SPOP as EglN2 E3 ligase\",\n      \"pmids\": [\"28089830\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"EglN2 acts as an FBW7 ubiquitin ligase substrate contributing to breast tumorigenesis; FBW7 overexpression leads to EglN2 downregulation in a GSK3β-dependent manner; depletion of FBW7 leads to EglN2 upregulation.\",\n      \"method\": \"FBW7 overexpression and knockdown; GSK3β inhibition; protein stability assays; co-immunoprecipitation; C3Tag transgenic mouse model\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP, genetic manipulation of FBW7/GSK3β, protein stability assays; single lab; GSK3β dependence confirmed\",\n      \"pmids\": [\"28036276\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PHD1 interacts with leucyl tRNA synthetase (LRS) and stabilizes it in a hydroxylation-independent manner; this interaction is promoted during oxygen and amino acid depletion and protects LRS from degradation; PHD1 knockout mice show impaired mTORC1 activation in response to leucine (but not growth factors or eccentric contractions), reduced muscle mass, and decreased LRS protein content.\",\n      \"method\": \"Co-immunoprecipitation of PHD1 with LRS; PHD1 catalytic mutant (hydroxylation-dead); PHD1KO mice; mTORC1 activity assays; leucine stimulation experiments; LRS activity measurements in human muscle biopsies\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal co-IP, catalytic mutant establishing hydroxylation independence, genetic knockout with specific mTORC1 readout, human validation; multiple orthogonal methods\",\n      \"pmids\": [\"31924757\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"EGLN2 is a substrate of the E3 ubiquitin ligase MDM2, which interacts with the N-terminal of EGLN2 and mediates its K48-linked poly-ubiquitination, thereby facilitating proteasomal degradation of EGLN2.\",\n      \"method\": \"Co-immunoprecipitation of EGLN2 with MDM2; ubiquitination assay (K48 linkage); protein stability assays; domain mapping (N-terminal EGLN2)\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP, K48-specific ubiquitination assay, domain mapping; single lab, multiple methods\",\n      \"pmids\": [\"34687132\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PHD1 hydroxylates Beclin1 on proline 54; VHL directly binds Beclin1 after PHD1-mediated hydroxylation; this binding inhibits the association of Beclin1-VPS34 complexes with ATG14L, thereby inhibiting autophagy initiation in response to nutrient deficiency; expression of non-hydroxylatable Beclin1 P54A abrogates VHL-mediated autophagy inhibition.\",\n      \"method\": \"In vitro hydroxylation assay; co-immunoprecipitation of VHL with Beclin1; P54A mutagenesis of Beclin1; Beclin1-VPS34-ATG14L complex assays; autophagy flux measurements; xenograft tumor models\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct in vitro hydroxylation, mutagenesis (P54A), reconstitution of VHL-Beclin1 interaction, multiple orthogonal methods including in vivo models\",\n      \"pmids\": [\"38360997\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Loss of EGLN2 in ALS models protects motor neurons and induces an astrocyte-specific downregulation of interferon-stimulated genes mediated via the STING protein; genetic deletion of EGLN2 restores this interferon response in patient iPSC-derived astrocytes.\",\n      \"method\": \"Egln2 genetic knockout; antisense oligonucleotide knockdown; zebrafish and mouse ALS models; single-nucleus RNA sequencing; iPSC-derived astrocyte experiments; STING pathway analysis\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic loss-of-function in multiple in vivo models with snRNA-seq pathway analysis; STING link established; single lab\",\n      \"pmids\": [\"39255062\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"PHD1 hydroxylates RepoMan (CDCA2) on proline 604; siRNA depletion of PHD1 (but not PHD2) increases H3T3 phosphorylation in prometaphase-arrested cells; the non-hydroxylatable RepoMan P604A mutant reduces interaction of RepoMan with PP2A-B56γ, delays completion of mitosis, causes defects in chromosome alignment and segregation, and increases cell death.\",\n      \"method\": \"Mass spectrometry identification of P604 hydroxylation; siRNA depletion of PHD1/PHD2; RepoMan P604A mutagenesis; co-immunoprecipitation of RepoMan with PP2A-B56γ; H3T3 phosphorylation immunostaining; live-cell imaging of mitosis\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — MS identification of hydroxylation site, mutagenesis, co-IP, functional mitotic assays; preprint with multiple orthogonal methods but not yet peer-reviewed\",\n      \"pmids\": [\"bio_10.1101_2025.05.06.652400\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"PHD1 inhibitors were identified with a novel monodentate binding mode; X-ray crystallography showed the triazolo N1 atom coordinates in a monodentate interaction with the active site Fe2+ ion, while the benzonitrile group accepts a hydrogen bond from Asn315.\",\n      \"method\": \"X-ray crystallography of PHD1-inhibitor complex; structure-activity relationship analysis\",\n      \"journal\": \"Journal of medicinal chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — crystal structure with functional binding mode identified; single study, primarily pharmacological focus\",\n      \"pmids\": [\"28594552\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Elevation of intracellular alpha-ketoglutarate inhibits RANKL-induced osteoclastogenesis by suppressing NF-κB signaling in a PHD1 (EGLN2)-dependent manner; blockade of PHD1 expression (but not PHD2 or PHD3) reverses this suppression of RANKL-activated NF-κB signaling and antagonizes the inhibitory effects on osteoclastogenesis.\",\n      \"method\": \"PHD1/PHD2/PHD3 siRNA knockdown; NF-κB reporter assay; RANKL-induced osteoclast differentiation assay; DMOG (PHD competitive inhibitor) treatment\",\n      \"journal\": \"Nutrients\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — isoform-specific siRNA with NF-κB reporter and differentiation assays; single lab, multiple methods\",\n      \"pmids\": [\"36771407\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"PHD1 (all three PHD isoforms) interacts with IKKα/β; overexpression of PHD1 and PHD2 (but PHD3 to a lesser extent) markedly reduces IKKα/β protein levels in a manner requiring PHD1/PHD2 active sites; PHD1 overexpression decreases mRNA levels of IL-1β, a downstream NF-κB target; FIH-1 does not interact with IKKα/β (negative finding).\",\n      \"method\": \"Co-immunoprecipitation of PHDs with IKKα/β; active-site mutants of PHD1/2/3; IL-1β mRNA measurement; IKKα/β protein level assays after PHD overexpression\",\n      \"journal\": \"The Journal of toxicological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP with active-site mutants establishing catalytic dependence; single lab, multiple isoforms compared\",\n      \"pmids\": [\"40024754\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"EGLN2/PHD1 is a nuclear, iron(II)- and 2-oxoglutarate-dependent prolyl hydroxylase that regulates the stability of HIF-α subunits by hydroxylating specific proline residues, targeting them for VHL-mediated ubiquitination and proteasomal degradation; beyond HIF, it directly hydroxylates additional substrates including FOXO3a (blocking USP9x binding and promoting FOXO3a degradation, thereby relieving Cyclin D1 repression), Cep192 (promoting SCF(Skp2)-mediated ubiquitination to regulate centrosome duplication and cell-cycle progression), Beclin1 (enabling VHL binding to suppress autophagy), and RepoMan/CDCA2 (regulating PP2A-B56γ interaction and mitotic progression); in a hydroxylation-independent manner, PHD1 stabilizes leucyl tRNA synthetase to sustain mTORC1 responses to leucine, and associates with the NRF1-PGC1α complex to promote mitochondrial gene transcription; PHD1 substrate selectivity and activity are regulated by CDK2/4/6-mediated phosphorylation at S130, while PHD1 protein abundance is controlled by SPOP and FBW7 E3 ubiquitin ligases and by MDM2-mediated K48-linked ubiquitination.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"EGLN2/PHD1 is a nuclear iron(II)- and 2-oxoglutarate-dependent prolyl hydroxylase that initiates regulated proteolysis of its substrates and broadly couples oxygen/metabolic status to cell-cycle, metabolic, and stress-response programs [#0, #1]. Its founding activity is hydroxylation of conserved prolines in HIF-1\\u03b1/HIF-2\\u03b1 within the LXXLAP motif, marking HIF-\\u03b1 for ubiquitin-mediated degradation; PHD1 contributes non-redundantly with PHD2/PHD3, and its catalytic core depends on the 2His-1-carboxylate iron motif and the 2-oxoglutarate-binding arginine [#0, #1, #2, #3]. Beyond HIF, PHD1 hydroxylates a defined set of substrates to control proteostasis and complex assembly: it hydroxylates FOXO3a to block USP9x-mediated deubiquitination and drive FOXO3a degradation, relieving repression of Cyclin D1 in estrogen-dependent breast cancer in a HIF-independent, catalysis-dependent manner [#9, #12]; it hydroxylates Cep192 at Pro1717 to recruit SCF(Skp2) for centrosome-duplication control [#11]; it hydroxylates Beclin1 at Pro54 to enable VHL binding and suppress autophagy initiation [#23]; and it hydroxylates RepoMan/CDCA2 at Pro604 to regulate PP2A-B56\\u03b3 interaction and mitotic progression [#25]. PHD1 also acts through hydroxylation-independent routes\\u2014stabilizing leucyl tRNA synthetase to sustain leucine-driven mTORC1 signaling and muscle mass [#21], and associating with the NRF1-PGC1\\u03b1 complex on chromatin to promote mitochondrial gene transcription and respiration [#16]. Substrate selectivity is gated by CDK2/4/6 phosphorylation at Ser130, which lowers activity toward HIF1\\u03b1 while raising activity toward Cep192 [#15], and PHD1 abundance is controlled by the E3 ligases SPOP, FBW7, and MDM2 [#19, #20, #22]. Physiologically, Phd1 loss reprograms glucose metabolism toward anaerobic/pentose-phosphate flux to protect muscle and neurons against ischemia [#5, #17], and a germline loss-of-function mutation in PHD1 is associated with pheochromocytoma/paraganglioma and polycythemia [#13].\",\n  \"teleology\": [\n    {\n      \"year\": 2002,\n      \"claim\": \"Established that EGLN2/PHD1 is an enzyme rather than a passive HIF binder, defining the catalytic chemistry that links oxygen availability to HIF-\\u03b1 fate.\",\n      \"evidence\": \"In vitro enzymatic assays with active-site mutagenesis and oxygen isotope tracing; reconstituted LXXLAP-motif mutagenesis across PHD isoforms\",\n      \"pmids\": [\"12039559\", \"12181324\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve PHD1-specific substrate preference beyond HIF\", \"Cellular contribution relative to other isoforms untested in this work\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Showed that PHD isoforms act non-redundantly with abundance-dependent and site-specific contributions, framing PHD1 as one functionally distinct arm of HIF regulation.\",\n      \"evidence\": \"Individual siRNA knockdown of each PHD across multiple cell types with site-specific hydroxylation readouts\",\n      \"pmids\": [\"15247232\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define non-HIF substrates\", \"Mechanism of isoform site selectivity unresolved\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Demonstrated that PHD1 gain-of-function suppresses HIF/VEGF output and tumor growth, establishing a tumor-relevant consequence of HIF hydroxylation.\",\n      \"evidence\": \"PHD1 overexpression in colon carcinoma cells with xenograft tumor model and microvessel/HIF immunostaining\",\n      \"pmids\": [\"14695194\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Gain-of-function only\", \"Endogenous PHD1 contribution not isolated\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Revealed that PHD1 is produced as two alternatively initiated isoforms differing in stability and regulation, indicating layered control of PHD1 protein levels.\",\n      \"evidence\": \"Start-codon mutagenesis, activity/stability assays, and Co-IP with Siah ligases\",\n      \"pmids\": [\"16509823\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Dominant degradation pathway under physiological conditions unresolved\", \"Functional distinction between isoforms in vivo untested\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identified PHD1 as a metabolic regulator in vivo, showing that Phd1 loss reprograms muscle glucose metabolism to confer ischemia tolerance largely independent of HIF-driven angiogenesis.\",\n      \"evidence\": \"Phd1 knockout mice with metabolic profiling, Hif-2\\u03b1 epistasis, and ischemic muscle histology\",\n      \"pmids\": [\"18176562\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct PPAR\\u03b1-pathway substrate of PHD1 not defined\", \"Tissue-specificity of the metabolic switch unresolved\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Provided the first phospho-regulatory layer on PHD1, showing PKC\\u03b1 phosphorylation sites tune catalytic activity.\",\n      \"evidence\": \"Recombinant PHD1 with in vitro kinase assays, site-directed mutagenesis, and activity measurements\",\n      \"pmids\": [\"18710826\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of these sites not established\", \"Did not link phosphorylation to substrate selectivity\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Defined PHD1 as an exclusively nuclear hydroxylase imported via importin \\u03b1/\\u03b2, distinguishing its compartment from cytoplasm-cycling PHD2 and rationalizing nuclear substrate access.\",\n      \"evidence\": \"Subcellular fractionation, importin inhibition, NLS mutagenesis, and microscopy\",\n      \"pmids\": [\"19631610\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether localization is regulated by signaling untested\", \"Link to specific nuclear substrates not made here\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Uncovered a HIF-independent oncogenic function: PHD1 catalytic activity sustains Cyclin D1 and estrogen-dependent breast tumorigenesis.\",\n      \"evidence\": \"EglN2 knockout mice, breast cancer siRNA, catalytic-mutant studies, and Cyclin D1 rescue\",\n      \"pmids\": [\"19878873\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct hydroxylation substrate linking PHD1 to Cyclin D1 not yet identified in this work\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Showed PHD1 can act as a non-catalytic protein partner, stabilizing and repressing ATF4 without hydroxylating it, broadening PHD1 function beyond proline hydroxylation.\",\n      \"evidence\": \"Reciprocal Co-IP, negative in vitro hydroxylation assay, and ATF4 reporter/stability assays\",\n      \"pmids\": [\"21951999\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis of PHD1-ATF4 binding unknown\", \"Physiological context of ATF4 repression untested\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identified Cep192 as a direct hydroxylation substrate coupling PHD1 to centrosome duplication and ciliogenesis via SCF(Skp2)-mediated degradation.\",\n      \"evidence\": \"Loss-of-function, MS site identification, P1717 mutagenesis, SCF(Skp2) Co-IP, and centrosome/cilia imaging\",\n      \"pmids\": [\"23932902\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Oxygen-dependence of Cep192 hydroxylation in vivo not defined\", \"Crosstalk with cell-cycle phosphorylation not yet linked\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Connected PHD1 catalysis to its Cyclin D1 phenotype by showing FOXO3a hydroxylation blocks USP9x binding and drives FOXO3a degradation, relieving Cyclin D1 repression.\",\n      \"evidence\": \"In vitro hydroxylation with MS site mapping, FOXO3a-USP9x Co-IP, stability assays, and Cyclin D1 readouts\",\n      \"pmids\": [\"24990963\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative contribution of FOXO3a vs other substrates to Cyclin D1 unresolved\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identified CDK2/4/6 phosphorylation at Ser130 as a substrate-switch that biases PHD1 away from HIF1\\u03b1 toward Cep192, integrating PHD1 into cell-cycle control.\",\n      \"evidence\": \"In vitro CDK kinase assays, phospho-S130 antibody, cell-cycle synchronization, Co-IP, and substrate activity assays\",\n      \"pmids\": [\"26644182\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether S130 also reroutes activity to FOXO3a/Beclin1/RepoMan untested\", \"Relation to PKC\\u03b1 sites unclear\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defined a hydroxylation-independent transcriptional co-activator role, with EglN2 joining the NRF1-PGC1\\u03b1 complex on chromatin to drive mitochondrial gene expression and respiration.\",\n      \"evidence\": \"Reciprocal Co-IP, ChIP, expression profiling, respiration and mtDNA measurements with siRNA\",\n      \"pmids\": [\"26492917\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether chromatin association requires catalytic residues untested\", \"Direct DNA/chromatin contacts undefined\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Linked PHD1 to genotoxic stress response, showing it reinforces p53-p38\\u03b1 interaction and p53 activation enabling nucleotide excision repair after chemotherapy.\",\n      \"evidence\": \"Isoform-specific siRNA, p53-p38\\u03b1 Co-IP, phospho-p53 S15 westerns, XPB interaction, and 5-FU xenograft\",\n      \"pmids\": [\"26290450\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether PHD1 hydroxylates a component of this complex unknown\", \"Mechanism of p53-p38\\u03b1 reinforcement undefined\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Provided human disease genetics linking a germline PHD1 loss-of-function mutation to pheochromocytoma/paraganglioma and polycythemia through reduced stability/activity.\",\n      \"evidence\": \"Patient sequencing, stability and catalytic activity assays, and erythroid progenitor EPO-sensitivity assay\",\n      \"pmids\": [\"25263965\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-variant evidence with limited mechanistic follow-up\", \"Causal substrate driving the tumor/polycythemia phenotype unspecified\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Extended the neuroprotective metabolic role, showing PHD1 deficiency boosts pentose-phosphate flux and redox buffering to protect neurons from ischemia.\",\n      \"evidence\": \"PHD1 knockout mice, brain ischemia model, metabolic flux and ROS analysis, and antisense oligonucleotide rescue\",\n      \"pmids\": [\"26774962\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct molecular target controlling the metabolic shift not defined\", \"Cell-type contribution within brain unresolved\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Showed PHD1 activity can be drug-induced to degrade HIF-1\\u03b1, linking docetaxel/JNK2 signaling to PHD1-driven HIF turnover and cancer cell death under hypoxia.\",\n      \"evidence\": \"JNK2 and PHD1 siRNA, pharmacological inhibition, HIF-1\\u03b1 ubiquitination/reporter assays, and xenograft\",\n      \"pmids\": [\"27263528\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which JNK2 activates PHD1 undefined\", \"Whether activation involves a known phospho-site untested\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identified SPOP and androgen-receptor signaling as a degradation/transcription axis controlling EglN2 abundance in prostate cancer.\",\n      \"evidence\": \"SPOP-EglN2 Co-IP, ubiquitination assays, SPOP mutants, AR transcription assays, and tumor models\",\n      \"pmids\": [\"28089830\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Degron in EglN2 recognized by SPOP not mapped\", \"Downstream substrate consequences of EglN2 accumulation untested\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Added FBW7 as a GSK3\\u03b2-dependent E3 ligase for EglN2 relevant to breast tumorigenesis, multiplying the routes controlling PHD1 stability.\",\n      \"evidence\": \"FBW7 overexpression/knockdown, GSK3\\u03b2 inhibition, stability assays, Co-IP, and transgenic mouse model\",\n      \"pmids\": [\"28036276\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Phosphodegron priming sites not mapped\", \"Interplay with SPOP/MDM2 unresolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Provided a structural view of the PHD1 active site, defining a monodentate iron-coordinating inhibitor binding mode and an Asn315 hydrogen-bond contact.\",\n      \"evidence\": \"X-ray crystallography of PHD1-inhibitor complex and structure-activity analysis\",\n      \"pmids\": [\"28594552\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No substrate-bound structure\", \"Basis of substrate selectivity not addressed structurally\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Established a hydroxylation-independent scaffolding role coupling PHD1 to nutrient signaling: PHD1 stabilizes leucyl tRNA synthetase to sustain leucine-driven mTORC1 and muscle mass.\",\n      \"evidence\": \"PHD1-LRS Co-IP, catalytic-dead mutant, PHD1KO mice, leucine-specific mTORC1 assays, and human muscle biopsies\",\n      \"pmids\": [\"31924757\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of PHD1-LRS protection undefined\", \"Mechanism linking oxygen/amino-acid depletion to the interaction unresolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Added MDM2 as an E3 ligase mediating K48-linked ubiquitination of EGLN2 via its N-terminus, further defining the proteostatic network governing PHD1.\",\n      \"evidence\": \"EGLN2-MDM2 Co-IP, K48-linkage ubiquitination assay, stability assays, and domain mapping\",\n      \"pmids\": [\"34687132\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological/cell-context where MDM2 dominates unclear\", \"Relationship to SPOP and FBW7 pathways untested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Linked PHD1 to bone biology, showing alpha-ketoglutarate suppresses RANKL-induced osteoclastogenesis through PHD1-dependent NF-\\u03baB inhibition.\",\n      \"evidence\": \"Isoform-specific siRNA, NF-\\u03baB reporter, osteoclast differentiation assay, and DMOG treatment\",\n      \"pmids\": [\"36771407\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct PHD1 substrate in NF-\\u03baB pathway not identified\", \"Whether catalytic activity is required not tested here\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Defined PHD1 control of autophagy, showing Beclin1 Pro54 hydroxylation enables VHL binding that blocks Beclin1-VPS34 association with ATG14L to inhibit autophagy initiation.\",\n      \"evidence\": \"In vitro hydroxylation, VHL-Beclin1 Co-IP, P54A mutagenesis, complex-assembly assays, autophagy flux, and xenografts\",\n      \"pmids\": [\"38360997\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Oxygen-tension dependence of this regulation under physiology not fully defined\", \"Crosstalk with PHD1's metabolic roles unresolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Implicated EGLN2 in neurodegeneration, showing its loss protects motor neurons in ALS models and restores STING-mediated astrocytic interferon responses.\",\n      \"evidence\": \"Egln2 knockout/ASO knockdown in zebrafish and mouse ALS models, snRNA-seq, and patient iPSC-astrocyte experiments\",\n      \"pmids\": [\"39255062\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct PHD1 substrate in the STING/interferon axis unidentified\", \"Catalytic dependence of the effect untested\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Extended PHD1's mitotic role, showing RepoMan/CDCA2 Pro604 hydroxylation governs RepoMan-PP2A-B56\\u03b3 interaction and faithful chromosome segregation.\",\n      \"evidence\": \"MS site identification, isoform-specific siRNA, P604A mutagenesis, PP2A-B56\\u03b3 Co-IP, H3T3 phospho-imaging, and live-cell mitosis imaging (preprint)\",\n      \"pmids\": [\"bio_10.1101_2025.05.06.652400\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Preprint not yet peer-reviewed\", \"Integration with Cep192-based mitotic control unresolved\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Added a catalysis-dependent route by which PHD1/PHD2 lower IKK\\u03b1/\\u03b2 levels and dampen NF-\\u03baB target expression, complementing the osteoclast NF-\\u03baB findings.\",\n      \"evidence\": \"PHD-IKK\\u03b1/\\u03b2 Co-IP, active-site mutants, IL-1\\u03b2 mRNA measurement, and IKK protein-level assays\",\n      \"pmids\": [\"40024754\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether IKK\\u03b1/\\u03b2 are direct hydroxylation substrates not shown\", \"PHD1 vs PHD2 relative contribution unresolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How CDK/PKC phosphorylation, multiple competing E3 ligases, and oxygen/metabolite levels are integrated to choose among PHD1's many catalytic and non-catalytic substrates in a given cell remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model of substrate prioritization\", \"No substrate-bound structures to explain selectivity\", \"Tissue-specific dominant substrates not defined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016491\", \"supporting_discovery_ids\": [0, 1, 6]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 1, 11, 12, 23, 25]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [16]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [21, 10]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [8]},\n      {\"term_id\": \"GO:0005730\", \"supporting_discovery_ids\": [16]},\n      {\"term_id\": \"GO:0005815\", \"supporting_discovery_ids\": [11]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [0, 2, 18]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [11, 15, 25]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [23]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [5, 16, 17]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [12, 19, 22, 21]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [21, 27, 28]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [24, 28]}\n    ],\n    \"complexes\": [\n      \"NRF1-PGC1\\u03b1 transcriptional complex\"\n    ],\n    \"partners\": [\n      \"HIF1A\",\n      \"FOXO3\",\n      \"CEP192\",\n      \"BECN1\",\n      \"CDCA2\",\n      \"LARS\",\n      \"NRF1\",\n      \"MDM2\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}